The study relied on several loci associated with myeloma risk (Table 1), including variants in ULK4 (unc-51 like kinase 4); a missense variant in TNFRSF13B, which encodes a B cell activating factor (BAFF) receptor from the TNF receptor family called TACI (transmembrane activator and calcium-modulating cyclophilin ligand interactor); SNPs around the promoter and enhancer regions of CBX7 (chromobox 7); and, importantly, a SNP at 7p15.3 (rs4487645) that was independently confirmed in a GWAS that also implicated the 2q12.3 region in myeloma risk (Erickson et al., 2014). This evidence concerns the gene TNFSF13B and plasma cell myeloma.